Alector Inc. (ALEC)’s Financial Results Comparing With Apellis Pharmaceuticals Inc. (NASDAQ:APLS)

Alector Inc. (NASDAQ:ALEC) and Apellis Pharmaceuticals Inc. (NASDAQ:APLS) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alector Inc. 20 48.32 N/A -0.40 0.00
Apellis Pharmaceuticals Inc. 20 0.00 N/A -2.77 0.00

Table 1 demonstrates Alector Inc. and Apellis Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Alector Inc. and Apellis Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Alector Inc. 0.00% 0% 0%
Apellis Pharmaceuticals Inc. 0.00% -77.1% -60.8%

Liquidity

The Current Ratio and Quick Ratio of Alector Inc. are 7.9 and 7.9 respectively. Its competitor Apellis Pharmaceuticals Inc.’s Current Ratio is 15.2 and its Quick Ratio is 15.2. Apellis Pharmaceuticals Inc. can pay off short and long-term obligations better than Alector Inc.

Analyst Recommendations

The Recommendations and Ratings for Alector Inc. and Apellis Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alector Inc. 0 0 2 3.00
Apellis Pharmaceuticals Inc. 0 0 1 3.00

The upside potential is 35.68% for Alector Inc. with consensus target price of $27. Competitively the consensus target price of Apellis Pharmaceuticals Inc. is $45, which is potential 63.99% upside. The data provided earlier shows that Apellis Pharmaceuticals Inc. appears more favorable than Alector Inc., based on analyst belief.

Institutional and Insider Ownership

Institutional investors owned 59.1% of Alector Inc. shares and 66.1% of Apellis Pharmaceuticals Inc. shares. Alector Inc.’s share owned by insiders are 8.1%. Competitively, insiders own roughly 1.6% of Apellis Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alector Inc. 6.24% 11.86% 7.1% 0% 0% 17.33%
Apellis Pharmaceuticals Inc. -3.62% 9.83% 49.36% 105.82% 57.53% 111.75%

For the past year Alector Inc. was less bullish than Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.